Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 24, 2026, 2:06 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–41 of 17 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Severe Uncontrolled Asthma Clear all
Completed Phase 3 Interventional Results available

Study of Efficacy and Safety of QAW039 in Patients With Severe Asthma Inadequately Controlled With Standard of Care Asthma Treatment.

NCT02555683
View directory record Official record
Conditions
Asthma
Interventions
QAW039, Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
12 Years and older
Enrollment
894 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
55
States / cities
Birmingham, Alabama • Gilbert, Arizona • Litchfield Park, Arizona + 49 more
Source: ClinicalTrials.gov public record
Updated May 17, 2020 · Synced Jul 24, 2026, 2:06 AM EDT
Recruiting Phase 3 Interventional

A Study to Investigate GB-0895 Adjunctive Therapy in Adults and Adolescents With Severe Uncontrolled Asthma (SOLAIRIA-2)

NCT07359846
View directory record Official record
Conditions
Severe Asthma
Interventions
GB-0895, Placebo
Drug
Lead sponsor
Generate Biomedicines
Industry
Eligibility
12 Years to 80 Years
Enrollment
786 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
17
States / cities
Bakersfield, California • Inglewood, California • West Covina, California + 12 more
Source: ClinicalTrials.gov public record
Updated Jul 19, 2026 · Synced Jul 24, 2026, 2:06 AM EDT
Terminated Phase 2 Interventional

Study of Safety of CSJ117 in Participants With Moderate to Severe Uncontrolled Asthma

NCT04946318
View directory record Official record
Conditions
Asthma
Interventions
CSJ117, Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 75 Years
Enrollment
136 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
10
States / cities
Bakersfield, California • Huntington Beach, California • Los Angeles, California + 6 more
Source: ClinicalTrials.gov public record
Updated Oct 9, 2022 · Synced Jul 24, 2026, 2:06 AM EDT
Terminated Phase 3 Interventional

Phase III Long-Term Extension Study With Dexpramipexole

NCT06388889
View directory record Official record
Conditions
Eosinophilic Asthma
Interventions
Dexpramipexole Dihydrochloride
Drug
Lead sponsor
Areteia Therapeutics
Industry
Eligibility
18 Years to 99 Years
Enrollment
509 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
23
States / cities
Bakersfield, California • Northridge, California • Coral Gables, Florida + 13 more
Source: ClinicalTrials.gov public record
Updated Dec 14, 2025 · Synced Jul 24, 2026, 2:06 AM EDT
Completed Phase 3 Interventional Results available

A Study of the Safety and Effectiveness of Benralizumab to Treat Patients With Severe Uncontrolled Asthma.

NCT03170271
View directory record Official record
Conditions
Asthma
Interventions
Benralizumab (Medi-563), Placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 75 Years
Enrollment
660 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
100
States / cities
Birmingham, Alabama • Tucson, Arizona • Little Rock, Arkansas + 87 more
Source: ClinicalTrials.gov public record
Updated Oct 31, 2021 · Synced Jul 24, 2026, 2:06 AM EDT
Terminated Phase 3 Interventional

A Study to Assess the Effect of Dexpramipexole in Adolescents and Adults With Severe Eosinophilic Asthma (EXHALE-3)

NCT05813288
View directory record Official record
Conditions
Eosinophilic Asthma, Asthma; Eosinophilic, Asthma
Interventions
Dexpramipexole Dihydrochloride, Placebo
Drug
Lead sponsor
Areteia Therapeutics
Industry
Eligibility
12 Years to 99 Years
Enrollment
654 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
76
States / cities
Mobile, Alabama • Chandler, Arizona • Peoria, Arizona + 64 more
Source: ClinicalTrials.gov public record
Updated Dec 14, 2025 · Synced Jul 24, 2026, 2:06 AM EDT
Completed Phase 2 Interventional

Study to Assess the Efficacy and Safety of Atuliflapon in Moderate-to-Severe Uncontrolled Asthma

NCT05251259
View directory record Official record
Conditions
Asthma
Interventions
Atuliflapon, Placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 80 Years
Enrollment
670 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
64
States / cities
Birmingham, Alabama • Sheffield, Alabama • Phoenix, Arizona + 52 more
Source: ClinicalTrials.gov public record
Updated Jan 13, 2026 · Synced Jul 24, 2026, 2:06 AM EDT
Recruiting Phase 2 Interventional

A Study of KT-621 Administered Orally to Adult Participants With Moderate to Severe Eosinophilic Asthma

NCT07323654
View directory record Official record
Conditions
Eosinophilic Asthma
Interventions
KT-621, Placebo
Drug · Other
Lead sponsor
Kymera Therapeutics, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
264 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
27
States / cities
Lancaster, California • Long Beach, California • Northridge, California + 22 more
Source: ClinicalTrials.gov public record
Updated Jun 28, 2026 · Synced Jul 24, 2026, 2:06 AM EDT
Not yet recruiting Not applicable Interventional

PULmonary Stimulation for Asthma Relief

NCT07709754
View directory record Official record
Conditions
Moderate to Severe Asthma
Interventions
Spinal Cord Stimulation
Device
Lead sponsor
Spiro Medical, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
2
States / cities
Denver, Colorado • Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Jul 16, 2026 · Synced Jul 24, 2026, 2:06 AM EDT
Completed Phase 3 Interventional Results available

Study of Efficacy and Safety of QAW039 in Patients With Severe Asthma Inadequately Controlled With Standard of Care Asthma Treatment.

NCT02563067
View directory record Official record
Conditions
Asthma
Interventions
QAW039, Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
12 Years and older
Enrollment
877 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
18
States / cities
Little Rock, Arkansas • San Jose, California • Stockton, California + 14 more
Source: ClinicalTrials.gov public record
Updated May 2, 2021 · Synced Jul 24, 2026, 2:06 AM EDT
Active, not recruiting Phase 2 Interventional

A Long-Term Safety and Efficacy Study of Verekitug (UPB-101) in Adult Participants With Severe Asthma (VALOUR)

NCT06966479
View directory record Official record
Conditions
Severe Asthma
Interventions
Verekitug, Placebo
Drug
Lead sponsor
Upstream Bio Inc.
Industry
Eligibility
18 Years and older
Enrollment
396 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
28
States / cities
Bakersfield, California • Northridge, California • Upland, California + 21 more
Source: ClinicalTrials.gov public record
Updated May 13, 2026 · Synced Jul 24, 2026, 2:06 AM EDT
Completed Phase 2 Interventional Results available

Study to Evaluate Tezepelumab on Airway Inflammation in Adults With Uncontrolled Asthma (CASCADE)

NCT03688074
View directory record Official record
Conditions
Asthma, Bronchial Diseases, Respiratory Tract Diseases, Lung Diseases, Obstructive, Lung Diseases, Respiratory Hypersensitivity, Hypersensitivity, Immediate, Hypersensitivity, Immune System Diseases
Interventions
Tezepelumab, Placebo
Biological · Other
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 75 Years
Enrollment
116 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
5
States / cities
Denver, Colorado • New Haven, Connecticut • Boston, Massachusetts + 2 more
Source: ClinicalTrials.gov public record
Updated Feb 20, 2022 · Synced Jul 24, 2026, 2:06 AM EDT
Active, not recruiting Phase 4 Interventional

Study Assessing the Long-term Effect of Dupilumab on Prevention of Lung Function Decline in Adult Patients With Uncontrolled Moderate to Severe Asthma

NCT05097287
View directory record Official record
Conditions
Asthma
Interventions
Dupilumab, Placebo
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
1,339 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2029
U.S. locations
75
States / cities
Cullman, Alabama • Sheffield, Alabama • Chandler, Arizona + 66 more
Source: ClinicalTrials.gov public record
Updated Apr 15, 2026 · Synced Jul 24, 2026, 2:06 AM EDT
Completed Phase 3 Interventional Results available

Study to Evaluate Tezepelumab in Adults & Adolescents With Severe Uncontrolled Asthma

NCT03347279
View directory record Official record
Conditions
Asthma
Interventions
Experimental: Tezepelumab, Placebo
Biological · Other
Lead sponsor
AstraZeneca
Industry
Eligibility
12 Years to 80 Years
Enrollment
1,061 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
95
States / cities
Dothan, Alabama • Foley, Alabama • Gilbert, Arizona + 79 more
Source: ClinicalTrials.gov public record
Updated Nov 25, 2021 · Synced Jul 24, 2026, 2:06 AM EDT
Completed Phase 2 Interventional Results available

Study to Assess the Efficacy and Safety of MEDI3506 in Adults With Uncontrolled Moderate-to-severe Asthma

NCT04570657
View directory record Official record
Conditions
Asthma
Interventions
MEDI3506, Placebo
Biological · Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 65 Years
Enrollment
250 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
9
States / cities
Bakersfield, California • Los Angeles, California • Newport Beach, California + 6 more
Source: ClinicalTrials.gov public record
Updated Jan 29, 2024 · Synced Jul 24, 2026, 2:06 AM EDT
Terminated Phase 2 Interventional Results available

An Evaluation Of PF-03715455 In Moderate To Severe Uncontrolled Asthma

NCT02219048
View directory record Official record
Conditions
Asthma
Interventions
Placebo, PF-03715455
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 65 Years
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
28
States / cities
Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 22 more
Source: ClinicalTrials.gov public record
Updated Jun 11, 2019 · Synced Jul 24, 2026, 2:06 AM EDT
Recruiting Phase 3 Interventional

A Study to Investigate the Efficacy and Safety of Tezepelumab Compared With Placebo in Children 5 to < 12 Years Old With Severe Asthma

NCT06023589
View directory record Official record
Conditions
Asthma
Interventions
Tezepelumab, Placebo
Biological · Other
Lead sponsor
AstraZeneca
Industry
Eligibility
5 Years to 11 Years
Enrollment
231 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2030
U.S. locations
30
States / cities
Montgomery, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 26 more
Source: ClinicalTrials.gov public record
Updated Jul 22, 2026 · Synced Jul 24, 2026, 2:06 AM EDT